Application Detail

Description of Medical Service

Folate receptor alpha (FRɑ) is a protein that is expressed in nearly all ovarian cancers and can be overexpressed in ovarian cancer solid tumours while being minimally expressed in normal tissue. The FRɑ-positive expression status may be determined using a validated immunohistochemistry (IHC) assay to detect the percentage of viable tumour cells with membrane staining for FRɑ. The test is used to determine eligibility for a potential new PBS subsidised treatment, mirvetuximab soravtansine.

Description of Medical Condition

The proposed treatment is intended for adults with epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumours are FRɑ-positive and are resistant to treatment with a platinum- containing chemotherapy regimen. Epithelial ovarian cancer is the most common type of ovarian cancer accounting for 90% of ovarian cancer cases.

Reason for Application

New MBS item (MSAC-PBAC co-dependent submission)

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 255 KB)
Application Summary (Word 30 KB)

PICO Set (PDF 576 KB)
PICO Set (Word 262 KB)

Consultation Survey

Consultation Survey

PASC Consultation
PASC consultation closes Friday 8 November 2024. Any consultation received after this date will automatically be included in the MSAC consultation for this application.

MSAC Consultation
MSAC consultation TBA – please subscribe to the MSAC email bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.

For further information please refer to PASC, ESC, MSAC Key Dates

For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

-

Meetings for this Application

PASC

12-13 December 2024

ESC

-

MSAC

-